eli lilly gip/glp-1 Medscape | Retatrutide, Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Lilly's Investigational Dual GIP and

Begin with half a serving (approximately 1015g of protein) and assess your tolerance over several days before increasing to a full serving

Clinical trials show semaglutide produces 15-22% body weight loss over 68 weeks, while metformin typically results in 2-3 pounds per year in non-diabetic patients

Both semaglutide and tirzepatide are long-acting GLP-1 medications, meaning they stay active in your system for several days, helping to regulate appetite, improve insulin function, and support weight loss all week long

GLP-1-targeted therapies have seen continuous updates over the past decades

Study data shows users experience 48% greater weight loss compared to medication alone

Bring documentation of your current dose, injection frequency (or daily oral dose), and the date of your most recent dose